Home » Stocks » ACRS

Aclaris Therapeutics, Inc. (ACRS)

Stock Price: $18.04 USD 0.07 (0.39%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
After-hours: $18.06 +0.02 (0.11%) Jan 21, 7:23 PM
Market Cap 768.26M
Revenue (ttm) 6.00M
Net Income (ttm) -56.44M
Shares Out 42.80M
EPS (ttm) -1.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $18.04
Previous Close $17.97
Change ($) 0.07
Change (%) 0.39%
Day's Open 18.16
Day's Range 17.15 - 19.50
Day's Volume 3,058,065
52-Week Range 0.75 - 19.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 day ago

Aclaris (ACRS) posts favorable preliminary topline results from a phase IIa study evaluating its investigational oral candidate ATI-450 for treating moderate to severe rheumatoid arthritis. Sh...

GlobeNewsWire - 1 day ago

WAYNE, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflam...

GlobeNewsWire - 2 days ago

WAYNE, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-infla...

The Motley Fool - 2 days ago

Investors are excited about the biotech's clinical trial results.

Market Watch - 2 days ago

Aclaris Therapeutics stock triples after positive data on arthritis treatment

InvestorPlace - 2 days ago

Aclaris Therapeutics (ACRS) stock is soaring higher on Tuesday after revealing results from a recent Phase 2a clinical trial. The post ACRS Stock Alert: Why Aclaris Therapeutics Is Up Over 200...

Benzinga - 2 days ago

A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-base...

Other stocks mentioned: CYAD, GRTS, MRUS, NERV, TENX
24/7 Wall Street - 2 days ago

Aclaris Therapeutics Inc. (NASDAQ: ACRS) shares more than doubled to start out the week after the company announced positive results from its midstage rheumatoid arthritis (RA) study.

Zacks Investment Research - 4 weeks ago

Investors need to pay close attention to Aclaris Therapeutics (ACRS) stock based on the movements in the options market lately.

GlobeNewsWire - 1 month ago

WAYNE, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-infla...

GlobeNewsWire - 2 months ago

WAYNE, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-infla...

Zacks Investment Research - 2 months ago

Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research - 2 months ago

Aclaris (ACRS) delivered earnings and revenue surprises of 13.79% and 1.61%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 months ago

WAYNE, Pa., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-infla...

Zacks Investment Research - 2 months ago

Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 3 months ago

Aclaris (ACRS) initiates a phase IIa study on ATI-1777, for the treatment of moderate-to-severe atopic dermatitis.

GlobeNewsWire - 3 months ago

WAYNE, Pa., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-infla...

Zacks Investment Research - 3 months ago

Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 4 months ago

WAYNE, Pa., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-in...

Zacks Investment Research - 5 months ago

Aclaris (ACRS) delivered earnings and revenue surprises of 17.65% and 64.21%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

WAYNE, Pa., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inf...

Zacks Investment Research - 5 months ago

Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 6 months ago

Aclaris (ACRS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

GlobeNewsWire - 6 months ago

WAYNE, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-...

Zacks Investment Research - 7 months ago

Aclaris (ACRS) announces that it supports an IND application to evaluate its oral investigational MK2 inhibitor compound, ATI-450, in hospitalized patients with COVID-19.

Benzinga - 7 months ago

Shares of micro-cap biopharma Aclaris Therapeutics Inc (NASDAQ: ACRS) were rallying Wednesday after the FDA gave its blessing for the company's investigational new drug application for a poten...

24/7 Wall Street - 7 months ago

Aclaris Therapeutics Inc. (NASDAQ: ACRS) says it has received an update from the U.S.

GlobeNewsWire - 7 months ago

WAYNE, Pa., June 17, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-...

GlobeNewsWire - 7 months ago

WAYNE, Pa., May 26, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced tha...

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor Aclaris Therapeutics

Zacks Investment Research - 8 months ago

Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 9 months ago

Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GlobeNewsWire - 9 months ago

WAYNE, Pa., March 31, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company, today announced that it has entered into a loan and secur...

Seeking Alpha - 10 months ago

Aclaris Therapeutics, Inc. (ACRS) CEO Neal Walker on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock ...

GlobeNewsWire - 1 year ago

•  Oral small molecule showed marked inhibition of TNFα, IL1β, IL8, and IL6 •  Preliminary data support progression to Phase 2a Proof of Concept Trials in Immuno-Inflammatory Diseases

GlobeNewsWire - 1 year ago

WAYNE, Pa., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced th...

Seeking Alpha - 1 year ago

Aclaris Therapeutics, Inc. (ACRS) CEO Neal Walker on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.

GlobeNewsWire - 1 year ago

WAYNE, Pa., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced it...

GlobeNewsWire - 1 year ago

WAYNE, Pa., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, announced today th...

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for October 3rd

Other stocks mentioned: ACA, ALGT, ALLY
Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for September 27th

Other stocks mentioned: AEP, ALLY
Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Aclaris Therapeutics, Inc. (ACRS).

Seeking Alpha - 1 year ago

Aclaris Therapeutics announced that it had achieved positive results in its Phase 3 THWART-2 study using A-101 45% topical solution to treat common warts.

Zacks Investment Research - 1 year ago

Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 1 year ago

Aclaris Therapeutics develops treatments for dermatological and immuno-inflammatory diseases.

GlobeNewsWire - 1 year ago

WAYNE, Pa., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, today announced i...

GlobeNewsWire - 1 year ago

WAYNE, Pa., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases...

GlobeNewsWire - 1 year ago

WAYNE, Pa., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases...

About ACRS

Aclaris Therapeutics, a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (... [Read more...]

Industry
Biotechnology
IPO Date
Oct 7, 2015
CEO
Neal Walker
Employees
75
Stock Exchange
NASDAQ
Ticker Symbol
ACRS
Full Company Profile

Financial Performance

In 2019, ACRS's revenue was $4.23 million, a decrease of -31.28% compared to the previous year's $6.15 million. Losses were -$161.35 million, 21.6% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ACRS stock is "Strong Buy." The 12-month stock price forecast is 20.00, which is an increase of 10.86% from the latest price.

Price Target
$20.00
(10.86% upside)
Analyst Consensus: Strong Buy